M.D. Ph.D. Craig B. Granowitz - 28 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
SVP, Chief Medical Officer
Signature
/s/ Craig B. Granowitz, M.D., Ph.D.
Issuer symbol
LXRX
Transactions as of
28 Feb 2026
Net transactions value
-$160,374
Form type
4
Filing time
03 Mar 2026, 07:19:33 UTC
Previous filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Granowitz Craig B SVP, Chief Medical Officer 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS /s/ Craig B. Granowitz, M.D., Ph.D. 03 Mar 2026 0001876655

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +35,790 +30% 156,042 28 Feb 2026 Direct F1
transaction LXRX Common Stock Options Exercise +74,226 +48% 230,268 28 Feb 2026 Direct F1
transaction LXRX Common Stock Options Exercise +202,260 +88% 432,528 28 Feb 2026 Direct F1
transaction LXRX Common Stock Tax liability $160,374 -109,098 -25% $1.47 323,430 28 Feb 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -35,790 -100% 0 28 Feb 2026 Common Stock 35,790 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -74,226 -50% 74,227 28 Feb 2026 Common Stock 74,226 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -202,260 -33% 404,520 28 Feb 2026 Common Stock 202,260 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.